IFNG and hemophagocytic syndrome: In 2018, emapalumab (Gamifant), an IFNγ antibody, was FDA-approved for the treatment of pediatric and adult patients with primary HLH who have refractory, recurrent, or progressive disease or intolerance with conventional HLH therapy [18].